Other treatment options, like hypomethylating drugs and BCL2 inhibitors, are commonly used to treat IDH-mutant hematologic malignancies like acute myeloid leukemia (AML) but have not been formally studied in the treatment of IDH-mutant gliomas. Here, IDH1 is linked to central nervous system cancer.